A5100709814- RNA modifications and cancer
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Cancer-related molecular mechanisms research
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Cancer, Hypoxia, and Metabolism
- Lipid metabolism and disorders
- HER2/EGFR in Cancer Research
- Ferroptosis and cancer prognosis
- Peptidase Inhibition and Analysis
- Galectins and Cancer Biology
- Neuroendocrine Tumor Research Advances
- Epigenetics and DNA Methylation
- Multiple and Secondary Primary Cancers
- Circular RNAs in diseases
- Renal and related cancers
- Microfluidic and Bio-sensing Technologies
- Drug-Induced Adverse Reactions
- Adipose Tissue and Metabolism
- Growth Hormone and Insulin-like Growth Factors
- Viral Infectious Diseases and Gene Expression in Insects
- Microbial Inactivation Methods
Second Hospital of Anhui Medical University
2013-2025
Anhui Medical University
2015-2025
Donghua University
2024
Guiyang Medical University
2024
Yuhuangding Hospital
2024
Qingdao University
2024
Chinese Academy of Sciences
2022
Jiangnan University
2022
State Key Laboratory of Food Science and Technology
2022
Chinese Academy of Medical Sciences & Peking Union Medical College
2019-2021
Abstract Diabetic cardiomyopathy (DCM) is one of the leading causes heart failure in patients with diabetes mellitus, limited effective treatments. The cardioprotective effects sodium‐glucose cotransporter 2(SGLT2) inhibitors have been supported by amounts clinical trials, which largely fills gap. However, underlying mechanism still needs to be further explored, especially terms its protection against cardiac fibrosis, a crucial pathophysiological process during development DCM. Besides,...
Nicorandil exerts myocardial protection through its antihypoxia and antioxidant effects. Here, we investigated whether it plays an anti-apoptotic role in diabetic cardiomyopathy. Sprague-Dawley rats were fed with high-fat diet; then single intraperitoneal injection of streptozotocin was performed. Rats fasting blood glucose (FBG) higher than 11.1 mmol/L selected as models. Eight weeks after the models built, treated nicorandil (7.5 mg/kg day 15 respectively) for 4 weeks. H9c2 cardiomyocytes...
We report a case of advanced triple-negative breast cancer (TNBC) with special clinical manifestations, in which durable remission was achieved after short-term administration toripalimab combined chemotherapy. The progress, advantages, and unique experience chemoimmunotherapy TNBC were examined. A patient local recurrence 2 years following surgery, inoperable large chest wall lesions positive PD-L1 as the main treated plus paclitaxel (albumin-bound) for 5 months partial remission....
This study aimed to investigate the event-based prospective memory (EBPM) and time-based (TBPM) in chemotherapy-induced cognitive impairment patients with breast cancer.Forty cancer who underwent adjuvant chemotherapy 40 age-matched education-matched healthy women were administered a battery of neuropsychological tests including EBPM TBPM tasks.A significant difference between controls was found scores on mini-mental state examination (t = -11.684, p < 0.01), verbal fluency test -7.939,...
4011 Background: CLDN18.2 expression has been observed in various solid tumors. In pancreatic ductal adenocarcinoma (PDAC), positive was reported nearly 60% patients (pts), indicating its potential as a novel target for anti-tumor therapy. IBI389 is an anti-CLDN18.2/CD3 bispecific antibody that induces immune synapse formations by linking CD3 molecules T-cell receptor complexes and antigens on the membrane of tumor cells. Herein, we report preliminary result from phase I study to evaluate...
170 Background: This is a randomized, double-blind, multicenter phase 2/3 study comparing the efficacy and safety of serplulimab (a novel anti-PD-1 antibody) plus bevacizumab XELOX chemotherapy vs. placebo as first-line treatment for metastatic colorectal cancer (mCRC). Our previous presentation at 2024 ASCO Meeting showed progression-free survival results. Here we present updated findings together with subgroup analysis results after median follow-up 31.0 months. Methods: A total 114...
796 Background: Sacituzumab tirumotecan (sac-TMT; also known as MK-2870/SKB264) is a TROP2 targeting ADC with hydrolytically cleavable linker and topoisomerase I inhibitor payload, KL610023 (average drug-to-antibody ratio, 7.4). In patients (pts) urothelial carcinoma (UC), treatment the anti-TROP2 sacituzumab govitecan led to treatment-related grade ≥3 neutropenia in 35% of pts febrile 10%. Cohort 9 MK-2870-001 (KL264-01; NCT04152499) evaluated sac-TMT monotherapy unresectable, locally...
Liver cancer, a highly aggressive malignancy, continues to present significant challenges in therapeutic management due its pronounced chemoresistance. This resistance, which undermines the efficacy of conventional chemotherapy and targeted therapies, is driven by multifaceted mechanisms, with increasing emphasis placed on protective role tumor microenvironment (TME). The hepatocellular carcinoma extracellular matrix (ECM), primary non-cellular component TME, has emerged as critical...
Breast cancer (BC) survivors frequently endure psychological distress following chemotherapy, with subjective memory decline being a prevalent aspect of chemotherapy-related cognitive impairment (CRCI). This study aimed to assess the influence on in BC CRCI and investigate potential underlying mechanisms. A total 104 who had completed chemotherapy were categorized based thermometer (DT) score into no-psychological group (NPD group, n = 51) (PD 53). The groups compared using Mini-Mental State...
IRF4, characterized by its unique helix-turn-helix DNA-binding motif, is a member of the interferon regulatory factor (IRF) family. It plays critical role in regulating host defense mechanisms, including innate...
Abstract Background: Overexpression of TROP2 (trophoblast cell surface antigen 2) in advanced gastric cancer is known as a poor prognostic factor. SKB264 (MK-2870) ADC developed with novel linker to conjugate the payload, belotecan-derivative topoisomerase I inhibitor. The affected by both extracellular pH-sensitive cleavage and intracellular enzymatic within tumor cells, which leads efficiently release payload inside cells well microenvironment exert its anti-tumor effects. Here, we report...
Abstract Background Combination of chidamide and anti‐PD‐L1 inhibitor produce synergistic anti‐tumor effect in advanced NSCLC patients resistant to anti‐PD‐1 treatment. However, the plus envafolimab has not been reported. Aims This study aimed evaluate efficacy toanti‐PD‐1 Materials Methods Eligible after therapy received envafolimab. The primary endpoint was objective response rate (ORR). secondary end points included disease control (DCR), progression‐free survival (PFS), safety....
2519 Background: CLDN18.2 expression has been observed in various solid tumors especially gastric cancer, indicating its potential as a novel target for anti-tumor therapy. IBI389 is an anti-CLDN18.2/CD3 bispecific antibody that induces immune synapse formations by linking CD3 molecules T-cell receptor complexes and antigens on the membrane of tumor cells. Herein, we report preliminary results from phase I study to evaluate safety efficacy patients (pts) with advanced tumors. Methods:...
Long noncoding RNAs (lncRNAs) are important regulators of gene expression and can affect a variety physiological processes. Recent studies have shown that immune-related lncRNAs play an role in the tumour immune microenvironment may potential application value treatment prognosis prediction patients. Epithelial ovarian cancer (EOC) is characterized by high incidence poor prognosis. However, there few on EOC. In this study, we focused associated with survival EOC.We downloaded mRNA data for...
Our previous studies showed that anti-β2M monoclonal antibodies (mAbs) have strong and direct apoptotic effects on multiple myeloma (MM) cells, suggesting mAbs might be developed as a novel therapeutic agent. In this study, we investigated the anti-MM of combination treatment with bortezomib (BTZ). results enhanced BTZ-induced apoptosis MM cell lines primary cells. Combination could also induce BTZ-resistant effect depended surface expression β2M BTZ up-regulated autophagy proteins, whereas...
Abstract Objective The purpose of the present study was to evaluate role co-treatment rosuvastatin (RSV) and dapagliflozin (DGZ) preconditioning in myocardium ischemia/reperfusion (I/R) injury further investigate underlying mechanism. Methods Sprague-Dawley (SD) rats ( n = 25) were divided into five groups randomly: (1) Sham, (2) I/R, (3) I/R + RSV (10 mg/kg), (4) IR DGZ (1 (5) mg/kg) mg/kg). model induced with 30 min left anterior descending occlusion followed by 120 reperfusion. Results In...
Abstract Anti‐angiogenesis is a promising therapeutic strategy for delaying tumour progression that offers, new hope gastric cancer targeted therapy. The purpose of this study was to investigate the precise mechanism by which Kin IRRE‐like protein 1 (KIRREL) contributes development cancer, particularly in terms angiogenesis. Differential expression KIRREL tissues and cells detected using quantitative real‐time polymerase chain reaction, western blotting immunohistochemistry. A bioinformatics...
124 Background: Immunotherapy significantly improved survival in patients with dMMR/MSI-H metastatic colorectal cancer (mCRC). However, whether the addition of immunotherapy to current standard-of-care treatments can improve efficacy pMMR/MSS mCRC, predominant type is unclear. This study aimed compare serplulimab, a novel PD-1 inhibitor, plus HLX04, bevacizumab biosimilar, and XELOX versus placebo as first-line treatment for mCRC. Methods: was randomized, double-blind, multicenter phase 2/3...
Establish an in situ model for investigating HNSCC, focusing on tumor growth, metastasis, and the immune microenvironment.
8089 Background: Tifcemalimab, a humanized IgG4 monoclonal antibody against B and T lymphocyte attenuator (BTLA), has shown preliminary anti-tumor activities in combination with toripalimab (anti-PD-1) as later line treatment for patients extensive-stage small cell lung cancer (ES-SCLC). We further conducted multi-cohort phase Ib/II study (NCT05664971) to evaluate the safety efficacy of tifcemalimab combined chemotherapy 1 st advanced cancer. Here, we report results from ES-SCLC cohort....